详文均见于”最近进展”（除非另有说明）; 同一文章可能见于本节内不同分类
Full articles can be found under “Recent Progress” unless specified; same reports may be classified under different categories in this section
乳腺癌 Breast cancer
12/22/2024: Trastuzumab Duocarmazine治疗HER 2 阳性晚期或转移性乳腺癌： III 期试验 (TULIP) Trastuzumab Duocarmazine inpPretreated HER 2+ advanced or metastatic breast cancer: A phase III trial
11/24/2024: KEYNOTE-522显示新辅助帕博利珠单抗加化疗延长高风险早期三阴性乳腺癌的总体生存 KEYNOTE-522 shows neoadjuvant pembrolizumab plus chemotherapy prolongs overall survival in high-risk early-stage triple-negative breast cancer
10/27/2024: Datopotamab–deruxtecan 联合 durvalumab治疗早期乳腺癌：I-SPY2.2试验 Datopotamab–deruxtecan in combination with durvalumab in early state breast cancer, I-SPY2.2 trial
10/13/2024: 新辅助免疫检查点抑制剂 (ICI) 联合化疗治疗早期乳腺癌: 荟萃分析 Neoadjuvant immune checkpoint inhibitors (ICI) plus chemotherapy in breast cancer: A meta-Analysis
10/12/2024: T-DXd用于激素受体阳性 (HR+), HER2低或 HER2 超低转移性乳腺癌 Trastuzumab deruxtecan (T-DXd) hormone receptor-positive (HR+), HER2-low or HER2-ultralow metastatic breast cancer: DESTINY-Breast06 (DB-06)
9/22/2024: FDA 批准ribociclib与芳香酶抑制剂联合用于治疗早期高风险乳腺癌 FDA approves ribociclib with an aromatase inhibitor for early high-risk breast cancer
9/7/2024: Sacituzumab Govitecan 治疗乳腺癌脑转移和复发性胶质母细胞瘤患者 Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma
8/11/2024: 新辅助化疗 ± Nivolumab 治疗雌激素受体+/HER2- 乳腺癌 Neoadjuvant chemotherapy ± nivolumab for ER+/HER2- breast cancer( CheckMate 7FL)
7/20/2024: A-BRAVE 试验：一项使用 avelumab 治疗新辅助化疗后残留疾病或高风险早期三阴性乳腺癌的 III 期试验 A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk
6/8/2024: 下一代 PARP1 选择性抑制剂 Saruparib 首次用于携带 BRCA1/2, PALB2 或 RAD51C/D 突变的患者 Next generation PARP1-selective inhibitor Saruparib first clinical trial in patients with BRCA1/2, PALB2 or RAD51C/D mutations
5/19/2024: 新辅助化疗淋巴结降期后省略腋窝淋巴结清扫 Omission of axillary lymph node dissection following nodal downstaging with neoadjuvant chemotherapy
5/11/2024: KEYNOTE-522: 派姆单抗治疗早期三阴性乳腺癌后残留癌症负担与无事件生存相关 KEYNOTE-522: Residual cancer burden with pembrolizumab in early-stage triple-negative breast cancer associated with event-free survival
4/20/2024: Abemaciclib 辅助内分泌疗法治疗激素受体阳性/HER2 阴性, 高风险早期乳腺癌 Adjuvant abemaciclib plus endocrine therapy for ER+/HER2- high-risk breast cancer: Results from MonarchE trial
4/6/2024: 氟维司群或/和Palbociclib或/和avelumab治疗 CDK4/6-/芳香酶-抑制剂治疗中出现进展的转移性乳腺癌 Fulvestrant and/or palbociclib and/or avelumab treat metastatic breast cancer that has progressed on CDK4/6-/aromatase-inhibitor combination
3/24/2024: 派姆单抗在乳腺癌新辅助治疗中的应用 Pembrolizumab in neoadjuvant therapy in breast cancer (KEYNOTE 756)
2/25/2024: 恩替司他, 纳武单抗和伊匹单抗治疗晚期 HER2 阴性乳腺癌 Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer
2/10/2024: 长期随访显示新副助 T-DM1 优于曲妥珠单抗治疗术后残留浸润性HER2+乳腺癌 Long-term follow-up demonstrated benefit of neoadjuvant T-DM1 over trastuzumab in HER2+ breast cancer patients with residual cancer after surgery
1/7/2024: MonarchE 试验中探索检测 ctDNA 的试点研究结果 Exploring ctDNA detection using a tumor-informed assay in the monarchE trial
肺癌 Lung cancer
12/8/2024: 局限期小细胞肺癌放化疗后使用 Durvalumab 可有益于总生存期 Durvalumab after chemoradiotherapy can improve overall survival in limited-stage small-cell lung cancer10/26/2024: Ifinatamab deruxtecan 用于广泛期小细胞肺癌 Ifinatamab deruxtecan in extensive-stage small cell lung cancer
10/19/2024: FDA 批准lazertinib与amivantamab-vmjw 联合用于非小细胞肺癌(NSCLC) FDA approved lazertinib with amivantamab-vmjw for non-small lung cancer
10/5/2024: FDA 批准新辅助/辅助 nivolumab 用于可切除非小细胞肺癌: CHECKMATE-77T FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer: CHECKMATE-77T
9/29/2024: FDA 批准 amivantamab-vmjw 联合化疗用于治疗 EGFR 外显子 19 缺失或 L858R 突变的非小细胞肺癌 FDA approves amivantamab-vmjw in combination with chemotherapy for non-small cell lung cancer with EGFR exon 19 deletion or L858R mutation
9/15/2024: 新辅助 Durvalumab (D) + 定向抗体-药物偶联物 + 化疗用于可切除非小细胞肺癌 Neoadjuvant durvalumab + directed antibody-drug conjugate + chemotherapy in resectable NSCLC (Neocoast-2 trial)
9/14/2024: 帕博利珠单抗联合化疗治疗酪氨酸激酶抑制剂耐药, EGFR 突变, 转移性非小细胞肺癌 Pembrolizumab in combination with chemotherapy for TKI‒resistant, EGFR–mutant, metastatic NSCLC
9/8/2024: 劳拉替尼与克唑替尼在晚期 ALK 阳性非小细胞肺癌中的疗效对比： CROWN 研究的 5 年结果 Lorlatinib versus Crizotinib in advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study
8/17/2024: FDA 批准 durvalumab 用于可切除非小细胞肺癌的新辅助/辅助治疗 FDA approves neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer
5/12/2024: PD-(L)1 阻断治疗非小细胞肺癌中产生耐药的基因组和免疫表型 Genomic and immunologic phenotypes of acquired resistance to PD-(L)1 blockade in NSCLC
5/4/2024: Atezolizumab 加贝伐单抗和化疗治疗 EGFR 或 ALK 突变非小细胞肺癌的III 期随机研究 Phase III study of atezolizumab plus bevacizumab and chemotherapy in EGFR- or ALK-mutated NSCLC
3/23/2024: 无驱动突变/改变的 IV 期非小细胞肺癌治疗：ASCO 指南，2023.3 版 Therapy for stage IV non–small cell lung cancer without driver alterations: ASCO living guideline, Version 2023.3
3/17/2024: 具有驱动突变/改变的 IV 期非小细胞肺癌的治疗：ASCO 指南，2023.3版本 Therapy for stage IV non–small cell lung cancer with driver alterations: ASCO Guideline, Version 2023.3
3/2/2024: 阿法替尼和化疗对罕见 EGFR 突变非小细胞肺癌 (NSCLC) Afatinib versus chemotherapy for NSCLC with uncommon EGFR mutation
2/25/2024: 第一个临床试验评估双特异性抗体治疗接受过抗 PD-(L)1疗法的非小细胞肺癌 (NSCLC) First clinical trial evaluating dual-specific antibody in NSCLC patients who failed anti-PD (L1) therapy
2/17/2024: 生物标志物导向的靶向治疗加 durvalumab 医治免疫疗法难治性非小细胞肺癌 Biomarker-directed targeted therapy (ceralasertib) plus durvalumab in checkpoint-inhibitor resistant non-small-cell lung ca
2/3/2024: Amivantamab与lazertinib相比于奥希替尼作为 EGFR 突变晚期非小细胞肺癌 (NSCLC) 的一线治疗Amivantamab plus lazertinib versus osimertinib as first-line therapy for EGFR-mutated NSCLC
1/13/2024: Tarlatamab 用于既往治疗过的小细胞肺癌 Tarlatamab therapy in previously treated small cell lung cancer
结直肠癌 Colorectal cancer
11/2/2024: 细胞周期蛋白依赖性激酶 4/6 抑制剂治疗伴有 GNAS 突变的腹膜粘液癌 Novel therapy using CDK 4/6 inhibitor for peritoneal mucinous carcinomatosis with GNAS mutations
10/20/2024: 局部晚期直肠癌的治疗：ASCO 指南 Management of locally advanced rectal cancer: ASCO guideline
10/6/2024: 完全新辅助治疗 (TNT) 联合非手术治疗治疗局部晚期直肠癌：NO-CUT 试验 Total neoadjuvant treatment (TNT) with non-operative management for pMMR locally advanced rectal cancer: NO-CUT trial
9/21/2024: 晚期胃肠道癌多药治疗方案中省略 5-FU 推注 Omission of bolus 5-FU from multidrug regimes for advanced GI cancers
6/15/2024: 局部晚期错配修复缺陷结肠癌的新辅助免疫疗法 Neoadjuvant immunotherapy for locally advanced dMMR colon cancer
5/18/2024: 过去 20 年来美国年轻人的结直肠癌发病率在上升 Colorectal cancer rates rising among U.S. youth over the past 20 years
1/21/2024: 具有分子残留疾病的结直肠癌患者的循环肿瘤 DNA (ctDNA) 动态变化与预后 Correlation of dynamic changes of ctDNA with outcome in colorectal cancer patients with molecular residual disease
肛门癌 Anal cancer
11/16/2024: Retifanlimab 联合化疗可延长肛门鳞状细胞癌患者的无进展生存期 Retifanlimab plus chemotherapy extends progression-free survival in patients with anal squamous cell carcinoma
4/7/2024: 阿替珠单抗(Atezolizumab) 联合改良多西他赛、顺铂和氟尿嘧啶作为晚期肛门癌的一线治疗 Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil (mDCF)as first-line treatment for advanced anal cancer
胰腺癌 Pancreatic cancer
7/13/2024: 树突状细胞的免疫疗法应用于胰腺癌切除后 Dendritic cell-based immunotherapy in patients with resected pancreatic cancer
7/7/2024: 围手术期 mFOLFIRINOX 治疗可切除胰腺癌非随机对照试验 Results from a phase II study of perioperative mFOLFIRINOX for resectable pancreatic cancer
4/13/2024: 非侵入性外泌体的液体活检用于早期检测胰腺导管腺癌 An exosome-based liquid biopsy for non-invasive, early detection of pancreatic ductal adenocarcinoma
1/14/2024: 立体定向放疗加或不加选择性歧化酶模拟物治疗胰腺癌 Stereotactic body radiotherapy (SBRT) with or without selective dismutase mimetic in pancreatic adenocarcinoma
肝细胞癌 Hepatocellular carcinoma
11/10/2024: 新辅助免疫检查点抑制剂治疗肝细胞癌 Neoadjuvant immune checkpoint inhibitors (ICI) treating hepatocellular carcinoma
6/1/2024: 晚期肝细胞癌的全身治疗：ASCO 指南 Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline4/14/2024: 个性化新抗原 DNA 疫苗和派姆单抗作为晚期肝细胞癌的二线治疗 Personalized neoantigen DNA vaccine and pembrolizumab as second-line treatment for advanced hepatocellular carcinoma
1/20/2024: Histotripsy系统用于治疗肝脏肿瘤 Histotripsy system used to treat liver tumors
胃和胃食管交界癌 Gastric/GEJ cancer
12/7/2024: 针对 HER2+ 不可切除或转移性胃或胃食管交界处腺癌的治疗有总生存期益处 KEYNOTE-811 Overall survival benefit combination therapy for HER2+ unresectable or metastatic G/GEJ adenocarcinoma KEYNOTE-811
9/21/2024: 晚期胃肠道癌多药治疗方案中省略 5-FU 推注 Omission of bolus 5-FU from multidrug regimes for advanced GI cancers
8/18/2024: 食管腺癌患者围手术期化疗 (FLOT) 优于新辅助放化疗 (CROSS) Perioperative chemotherapy (FLOT protocol) is better than neoadjuvant chemoradiation (CROSS protocol) in esophageal cancer (ESOPEC trial)
6/22/2024: III 期 CheckMate 649 试验: 晚期胃癌, 胃食管连接部癌和食管腺癌的一线 Nivolumab 联合化疗 Phase III CheckMate 649 Trial: First-line nivolumab plus chemotherapy for advanced gastric, GEJ, and esophageal adenocarcinoma
4/21/2024: 一线tiragolumab + atezolizumab 和化疗治疗食管鳞状细胞癌的III 期试验 A phase III study of first-line tiragolumab + atezolizumab and chemotherapy in esophageal squamous cell carcinoma
1/27/2024: FLOT 联合或不联合杜瓦鲁单抗用于胃和胃食管交界癌的病理完全缓解 Impact of FLOT +/- durvalumab on pCR rate in gastric/gastroesophageal junctional (GC/GEJ) cancer
胆道癌 Biliary tract cancer
11/23/2024: FDA 加速批准 zanidatamab用于治疗不可切除或转移性 HER2 阳性胆道癌 FDA grants accelerated approval to zanidatamab for unresectable or metastatic HER2+ biliary tract cancer
胃肠胰神经内分泌肿瘤 Gastroenteropancreatic neuroendocrine tumor
3/3/2024: [177Lu]Lu-DOTA-TATE （177Lu-DOTATATE）放射配体治疗第一线治疗晚期胃肠胰神经内分泌肿瘤 177Lu-DOTATATE for newly-diagnosed advanced gastroenteropancreatic neuroendocrine tumor
前列腺癌 Prostate cancer
11/17/2024: 派姆單抗合併化療治療小細胞/神經內分泌膀胱癌和前列腺癌 Pembrolizumab plus chemotherapy in small cell/neuroendocrine bladder and prostate cancers
3/16/2024: 阿比特龙 + 奥拉帕尼治疗转移性去势抵抗性前列腺癌 Abiraterone plus olaparib in patients with metastatic castration-resistant prostate ca
2/4/2024: Actinium-225-PSMA 放射配体治疗转移性去势抵抗性前列腺癌 Actinium-225-PSMA radioligand treating metastatic castration-resistant prostate cancer
肾癌 Kidney cancer
2/11/2024: 辅助派姆单抗相比于安慰剂治疗透明细胞肾细胞癌: KEYNOTE-564 研究结果 Adjuvant pembrolizumab versus placebo in clear cell renal cell carcinoma: results from the KEYNOTE-564 study
膀胱癌 Bladder cancer
12/1/2024: 围手术期 Durvalumab 联合新辅助化疗治疗膀胱癌 Perioperative Durvalumab with neoadjuvant chemotherapy in bladder cancer
11/30/2024: Nivolumab用于高风险肌层浸润性尿路上皮癌的辅助治疗：CheckMate 274 Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: CheckMate 274
11/17/2024: 派姆單抗合併化療治療小細胞/神經內分泌膀胱癌和前列腺癌 Pembrolizumab plus chemotherapy in small cell/neuroendocrine bladder and prostate cancers
子宫内膜癌 Endometrial cancer
3/30/2024: Dostarlimab 的组合治疗晚期子宫内膜癌 Dostarlimab combination treating advanced endometrial cancer
卵巢癌 Ovarian cancer
6/2/2024: Raludotatug deruxtecan 单药用于既往接受过治疗的卵巢癌患者 Monotherapy of Raludotatug deruxtecan in previously-treated ovarian cancer
宫颈癌 Cervical Cancer
11/3/2024: 帕博利珠单抗或安慰剂联合放化疗治疗新诊断的高风险局部晚期宫颈癌 Pembrolizumab or placebo with chemoradiotherapy for newly diagnosed, high-risk, locally advanced cervical cancer
黑色素瘤 Melanoma
7/6/2024: 三联疗法 nivolumab, relatlimab 和 ipilimumab在晚期黑色素瘤中的疗效和安全性 Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab in advanced melanoma
3/9/2024: FDA 批准首个细胞疗法治疗不可切除或转移性黑色素瘤 First cellular therapy for unresectable or metastatic melanoma approved by FDA
头颈癌 Head and neck cancer
4/27/2024: 新型 MDM-2 抑制剂 (Alrizomadlin) 治疗p53 野生型唾液腺癌 A novel MDM-2 inhibitor (Alrizomadlin) in p53 wild type salivary gland cancers
脑癌 Brain tumor
8/25/2024: CAR-T 细胞与复发性高级别脑癌 CAR-T cell therapy in recurrent high-grade glioma
甲状腺癌 Thyroid cancer
12/21/2024: 侵袭性甲状腺癌患者的双重免疫检查点抑制 Dual immune checkpoint inhibition in aggressive thyroid cancer
淋巴瘤 Lymphoma
11/9/2024: Nivolumab+AVD 治疗晚期经典霍奇金淋巴瘤 Nivolumab plus AVD in advanced-stage classic Hodgkin’s lymphoma
9/28/2024: Atezolizumab, venetoclax 和 obinutuzumab联合治疗 Richter 转化型弥漫性大 B 细胞淋巴瘤 (DLBCL) Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO)
9/1/2024: 最近进展 Recent Progress–>NX-5948 , 一种首次应用人类BTK 降解剂在难治性慢性淋巴细胞白血病患者中的应用 First in human BTK degrader, NX-5948 in refractory CLL patients
8/4/2024: Glofitamab 联合吉西他滨和奥沙利铂 (Gemox) 治疗复发/难治性弥漫性大 B 细胞淋巴瘤 Glofitamab in combination with gemcitabine/oxaliplatin (Gemox) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
7/21/2024: 复发性弥漫性大 B 细胞淋巴瘤的联合靶向治疗 Combination targeted therapy in relapsed diffuse large B-cell lymphoma
6/30/2024 Armored huCART19-IL18 用于 CD19 CAR T 细胞治疗后进展的复发/难治性淋巴瘤 Armored huCART19-IL18 in relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells
6/23/2024: 抗 CD19 嵌合抗原受体 T 细胞疗法治疗 Richter 转化 Anti-CD19 CAR-T therapy for Richter transformation
6/8/2024: 下一代 PARP1 选择性抑制剂 Saruparib首次用于携带 BRCA1/2, PALB2 或 RAD51C/D 突变的患者 Next generation PARP1-selective inhibitor Saruparib first clinical trial in patients with BRCA1/2, PALB2 or RAD51C/D mutations
5/25/2024: 同种异体 CD19 特异性 CAR-NK 细胞应用于CD19+ 的 B 淋细胞肿瘤 Allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors
5/5/2024: SYMPATICO试验：Ibrutinib联合 Venetoclax 可改善复发性套细胞淋巴瘤的无进展生存期 Ibrutinib plus venetoclax improves progression-free survival in relapsed mantle cell lymphoma (SYMPATICO trial)
肉瘤 Sarcoma
12/14/2024: 阿霉素-Trabectedin 联合Trabectedin维持治疗平滑肌肉瘤 Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
8/10/2024: FDA 批准vorasidenib用于治疗具有易感 IDH1 或 IDH2 突变的 2 级星形细胞瘤或少突胶质细胞瘤 FDA approves vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
8/3/2024: Unesbulin 联合达卡巴嗪治疗局部复发,转移性, 或难治性平滑肌肉瘤 Phase Ib study of Unesbulin plus dacarbazine for locally recurrent, metastatic or refractory leiomyosarcoma
6/29/2024: Afamitresgene autoleucel 治疗晚期滑膜肉瘤和粘液样圆细胞脂肪肉瘤 Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma
6/9/2024: 软组织肉瘤的新辅助放疗和手术联合或不联合派姆单抗 Neoadjuvant radiation and surgery with or without pembrolizumab for soft tissue sarcoma
2/18/2024: 新辅助免疫检查点阻断治疗腹膜后去分化脂肪肉瘤和四肢/躯干未分化多形性肉瘤 Neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma
多发性骨髓瘤 Multiple myeloma
8/24/2024: Belantamab Mafodotin, 泊马度胺和地塞米松在多发性骨髓瘤中的应用 Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma
5/26/2024: 5-氮杂胞苷和Venetoclax组合治疗多发性骨髓瘤 5-azacitidine and Venetoclax combination to multiple myeloma
1/28/2024: 达雷妥尤单抗, 硼替佐米, 来那度胺和地塞米松治疗多发性骨髓瘤 Daratumumab plus bortezomib, lenalidomide, and dexamethasone for multiple myeloma 肿瘤生物学和治疗/诊断新进展 Tumor biology & New treatment/diagnosis progress
1/7/2024: MonarchE 试验中探索检测 ctDNA 的试点研究结果 Exploring ctDNA detection using a tumor-informed assay in the monarchE trial
肿瘤生物学和治疗/诊断新进展 Tumor biology & New treatment/diagnosis progress
11/2/2024: 细胞周期蛋白依赖性激酶 4/6 抑制剂治疗伴有 GNAS 突变的腹膜粘液癌 Novel therapy using CDK 4/6 inhibitor for peritoneal mucinous carcinomatosis with GNAS mutations
6/16/2024: 首创泛素特异性肽酶 1 (USP1) 抑制剂的首次人体 I 期试验用于晚期实体瘤 First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor in advanced solid tumors
5/25/2024: 同种异体 CD19 特异性 CAR-NK 细胞应用于CD19+ 的 B 淋细胞肿瘤 Allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors4/28/2024: 人工智能模型和预测治疗反应 AI model and treatment responses prediction
4/14/2024: 个性化新抗原 DNA 疫苗和派姆单抗作为晚期肝细胞癌的二线治疗 Personalized neoantigen DNA vaccine and pembrolizumab as second-line treatment for advanced hepatocellular carcinoma
4/13/2024: 非侵入性外泌体的液体活检用于早期检测胰腺导管腺癌 An exosome-based liquid biopsy for non-invasive, early detection of pancreatic ductal adenocarcinoma
2/25/2024: 第一个临床试验评估双特异性抗体治疗接受过抗 PD-(L)1疗法的非小细胞肺癌 (NSCLC) First clinical trial evaluating dual-specific antibody in NSCLC patients who failed anti-PD (L1) therapy
2/17/2024: 生物标志物导向的靶向治疗加 durvalumab 医治免疫疗法难治性非小细胞肺癌 Biomarker-directed targeted therapy (ceralasertib) plus durvalumab in checkpoint-inhibitor resistant non-small-cell lung ca
流行病学 Epidemiology
8/31/2024: 血液中白细胞介素 6 的水平可预测 2 型糖尿病患者中与肥胖相关癌症风险 Circulating levels of interleukin-6 predict risk of obesity-related cancers in those with recently diagnosed type 2 diabetes7/29/2024: 纹身是恶性淋巴瘤的危险因素? Is tattoo a risk factor for malignant lymphoma?
7/14/2024: 使用胰高血糖素样肽 1 受体激动剂与 2 型糖尿病患者的 13 种肥胖相关癌症 Glucagon-like peptide 1(GLP-1) receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes
5/18/2024: 过去 20 年来美国年轻人的结直肠癌发病率在上升 Colorectal cancer rates rising among U.S. youth over the past 20 years
3/31/2024: 基因与环境相互作用分析用于了解红肉摄入量与结直肠癌风险之间的关系 Gene–environment interaction analyses to understand the relationship between red meat consumption and colorectal cancer risk
1/6/2024: 超加工食品, 肥胖与头颈癌和食管腺癌的风险：欧洲癌症与营养前瞻性调查的中介分析 Ultra-processed foods, adiposity and risk of head and neck cancer and esophageal adenocarcinoma: a mediation analysis in the European Prospective Investigation into Cancer and Nutrition
副作用 Side-effects
3/10/2024: 外用双氯芬酸预防卡培他滨所引起的手足综合征 Topical diclofenac for prevention of capecitabine-associated hand-foot Syndrome